Cardiovascular diseases are very common between older people and are very dangerous. Many complications can occur from these disorders included heart attacks and strokes. Eventually, with many cardiovascular disorders, heart failure might be the end result. Different diseases might also lead to heart failure, however it most commonly occurs due to certain problems in the heart.
A recent study conducted by a team of scientists from the Icahn School of Medicine at Mount Sinai was able to find that diabetes drugs are actually beneficial for patients with cardiovascular diseases. This includes the Empagliflozin which is an anti-diabetes drug. It has showed results to reverse heart failure and lowering the risk of it affecting patients. This study was published in the Journal of American College of Cardiology.
The study was led by a professor of Cardiology and Director of the Atherothrombosis Research Unit at the Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai called Juan Badimon.
He commented on his findings saying, “This drug could be a promising treatment for heart failure in both non-diabetic and diabetic patients. Our research can lead to a potential application in humans, save lives, and improve quality of life. This study confirmed our hypothesis that empagliflozin is an incredibly effective treatment for heart failure and not only an antidiabetic drug. Moreover, this study demonstrated that empagliflozin is useful for heart failure independently of a patient’s diabetic status. Importantly, empagliflozin switches cardiac metabolism toward fatty acid and ketone body consumption, thus allowing the production of more energy in the heart.”